Novoprotein Scientific Inc
SSE:688137
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
N
|
Novoprotein Scientific Inc
SSE:688137
|
2B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
88.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Novoprotein Scientific Inc
Glance View
Suzhou Novoprotein Scientific Co., Ltd. engages in the research and development, production, and sale of recombinant protein application solutions. The company is headquartered in Suzhou, Jiangsu and currently employs 665 full-time employees. The company went IPO on 2022-09-29. The firm is mainly engaged in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of related technical services. The firm's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The firm mainly conducts its businesses in domestic and overseas markets.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Novoprotein Scientific Inc is -65.9%, which is below its 3-year median of -38.8%.
Over the last 3 years, Novoprotein Scientific Inc’s Operating Margin has decreased from 47% to -65.9%. During this period, it reached a low of -72.8% on Mar 31, 2025 and a high of 47% on Aug 30, 2022.
